Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 9, 2019

Study Completion Date

September 9, 2019

Conditions
Kidney Cancer
Interventions
DRUG

Everolimus

10 mg by mouth once a day.

DRUG

Sunitinib

50 mg by mouth daily for 4 weeks on / 2 weeks off

Trial Locations (4)

77030

University of Texas MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute - University of Utah, Salt Lake City

02115

Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER